Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 70

1.

A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, Oprea TI, Cruciani G.

J Med Chem. 2011 Mar 24;54(6):1740-51. doi: 10.1021/jm101421d. Epub 2011 Feb 22.

2.

Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.

Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, Flemming C, Smith J, Purmal A, Isachenko N, Komarov PG, Gurova KV, Sartorelli AC, Marshall GM, Norris MD, Gudkov AV, Haber M.

Cancer Res. 2009 Aug 15;69(16):6573-80. doi: 10.1158/0008-5472.CAN-09-1075. Epub 2009 Aug 4.

3.

ABC efflux pump-based resistance to chemotherapy drugs.

Eckford PD, Sharom FJ.

Chem Rev. 2009 Jul;109(7):2989-3011. doi: 10.1021/cr9000226. Review. No abstract available.

PMID:
19583429
4.

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E.

Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61. doi: 10.1007/s00280-009-1041-6.

PMID:
19499221
5.

Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.

Mayur YC, Peters GJ, Prasad VV, Lemo C, Sathish NK.

Curr Cancer Drug Targets. 2009 May;9(3):298-306. Review.

PMID:
19442050
6.

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B.

Drug Discov Today. 2008 May;13(9-10):379-93. doi: 10.1016/j.drudis.2007.12.010. Epub 2008 Feb 20. Review.

PMID:
18468555
7.

High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent.

Winter SS, Lovato DM, Khawaja HM, Edwards BS, Steele ID, Young SM, Oprea TI, Sklar LA, Larson RS.

J Biomol Screen. 2008 Mar;13(3):185-93. doi: 10.1177/1087057108314610. Epub 2008 Feb 29.

PMID:
18310528
8.

High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.

Ivnitski-Steele I, Larson RS, Lovato DM, Khawaja HM, Winter SS, Oprea TI, Sklar LA, Edwards BS.

Assay Drug Dev Technol. 2008 Apr;6(2):263-76. doi: 10.1089/adt.2007.107.

PMID:
18205550
10.
11.

The pharmacology of cancer resistance.

O'Connor R.

Anticancer Res. 2007 May-Jun;27(3A):1267-72. Review.

12.

Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

Gillet JP, Efferth T, Remacle J.

Biochim Biophys Acta. 2007 Jun;1775(2):237-62. Epub 2007 Jun 6. Review.

PMID:
17572300
13.

Evaluation of drug-transporter interactions using in vitro and in vivo models.

Xia CQ, Milton MN, Gan LS.

Curr Drug Metab. 2007 May;8(4):341-63. Review.

PMID:
17504223
14.

Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Winter SS, Jiang Z, Khawaja HM, Griffin T, Devidas M, Asselin BL, Larson RS; Children's Oncology Group.

Blood. 2007 Sep 1;110(5):1429-38. Epub 2007 May 10. Erratum in: Blood. 2008 May 1;111(9):4830.

15.

ABCG2: determining its relevance in clinical drug resistance.

Robey RW, Polgar O, Deeken J, To KW, Bates SE.

Cancer Metastasis Rev. 2007 Mar;26(1):39-57. Review.

PMID:
17323127
16.

Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.

Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T.

J Clin Oncol. 2007 Feb 1;25(4):411-7. Epub 2006 Dec 18.

PMID:
17179098
17.

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.

Sarkadi B, Homolya L, Szakács G, Váradi A.

Physiol Rev. 2006 Oct;86(4):1179-236. Review.

PMID:
17015488
18.

In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.

Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M.

Int J Cancer. 2006 Jul 15;119(2):414-22.

19.

Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.

Jekerle V, Klinkhammer W, Reilly RM, Piquette-Miller M, Wiese M.

Cancer Chemother Pharmacol. 2007 Jan;59(1):61-9. Epub 2006 Apr 25.

PMID:
16636798
20.

Supplemental Content

Support Center